mRNA Technology Newsletter
Issue #40June 8, 20267 studies

mRNA vaccine boosted cancer immunotherapy survival rates by 70-80% in mice

This week brought major advances in mRNA technology, from next-generation COVID vaccines showing stronger immune responses to breakthrough applications in cancer therapy and toxin protection.

🎯 COVID mRNA Vaccines Show Promise as Cancer Therapy Boosters

A recent study found that repurposing COVID-19 mRNA vaccines alongside immune checkpoint inhibitors could fundamentally reshape cancer treatment:

  • COVID-19 mRNA-lipid nanoparticle vaccines reduced tumor burden by 70-80% in mouse models of melanoma and colon cancer when combined with immune checkpoint inhibitors
  • The vaccines work by triggering innate immune responses that break down the tumor's immunosuppressive environment, enabling stronger anti-tumor T cell responses
  • This approach could make immune checkpoint inhibitors effective even in cancer types that normally don't respond to these treatments

Why it matters: Since mRNA vaccines are already approved for human use, this represents an immediately translatable approach to boost cancer immunotherapy effectiveness without developing entirely new treatments.

🥈 Top 2% journal 🔗 Journal for immunotherapy of cancer Journal Article 🗓️ Jun 3

Key Findings

🧬 Next-Gen COVID Vaccine Shows Superior Immune Response

  • The NextCOVE trial with over 10,000 participants aged 12+ found that mRNA-1283 (10 µg) met non-inferiority criteria versus the current mRNA-1273 vaccine (50 µg)
  • Higher antibody levels were consistently linked to lower COVID-19 risk, with hazard ratios of 0.41 for XBB.1.5 variant protection
  • The new vaccine uses a smaller dose but elicited stronger neutralizing antibody responses than the current version
💡 This suggests next-generation mRNA vaccines could provide better protection with lower doses.
Top 20% journal 🔗 Human vaccines & immunotherapeutics Randomized Controlled Trial 🗓️ Jun 1

🔬 Antioxidant Nanoparticles Protect mRNA from Cellular Damage

  • Researchers developed antioxidant lipid nanoparticles (AOLNPs) that shield mRNA from oxidative stress, a major cause of therapeutic failure
  • AOLNPs preserved mRNA integrity and sustained high-level protein expression in multiple organ injury models
  • The antioxidant-enhanced particles led to improved regenerative outcomes and more efficient genome editing compared to conventional clinical LNPs
💡 This could enable mRNA therapies to work in challenging oxidative environments like inflamed or injured tissues.
🥈 Top 2% journal 🔗 Nature communications Journal Article 🗓️ Jun 4

💉 mRNA Antibody Cocktail Extends Treatment Window for Ricin Poisoning

  • An mRNA-delivered antibody cocktail provided complete protection against lethal ricin challenge for at least 14 days after a single dose in mice
  • The treatment worked even when given 10 hours after ricin exposure, significantly extending the therapeutic window
  • The mRNA approach showed a prolonged circulating half-life compared to traditional protein antibodies
💡 This demonstrates how mRNA platforms could rapidly produce antibody treatments for biological threats.
Top 20% journal 🔗 Applied microbiology and biotechnology Journal Article 🗓️ Jun 4

🫁 Lung Surfactant Boosts Pulmonary mRNA Delivery

  • Adding clinically-used lung surfactant Poractant alfa to lipid nanoparticles increased particle concentration by 10-fold compared to conventional formulations
  • Surfactant-enhanced nanoparticles showed several-fold increases in mRNA transfection efficiency while maintaining excellent safety
  • Intranasal administration led to enhanced protein expression in mouse lungs compared to standard nanoparticles
💡 This simple formulation change could significantly improve inhaled mRNA therapeutics for lung diseases.

🦠 New Mpox mRNA Vaccine Shows Strong Safety and Immune Response

  • BNT166a, encoding 4 key mpox virus antigens, induced binding antibodies against all target proteins with 100% response rates 2 weeks after the second dose in 64 participants
  • Neutralizing antibodies against mpox were detected in 62-92% of participants depending on dose, with higher rates in those previously vaccinated against smallpox
  • Most side effects were mild to moderate, with only 2 participants experiencing severe reactions in the highest dose group
💡 This quadrivalent mRNA approach could provide broader protection against mpox than current vaccines.
🥇 Top 1% journal 🔗 The Lancet. Infectious diseases Journal Article 🗓️ Jun 3

🔄 Continuous mRNA Purification Achieves 99.7% Impurity Removal

  • High-performance countercurrent membrane purification removed 99.7% of cytosine triphosphates from mRNA with no measurable mRNA loss using a 60-minute process
  • The system operated continuously for over 24 hours without membrane fouling while maintaining >97% mRNA yield
  • Proteinase K removal exceeded 94%, though was reduced when mRNA was present due to protein-RNA interactions
💡 This continuous purification method could make large-scale mRNA production more efficient and cost-effective.
Top 20% journal 🔗 Biotechnology and bioengineering Journal Article 🗓️ Jun 3

Implications

These advances show mRNA technology rapidly expanding beyond vaccines into cancer therapy, toxin protection, and improved delivery systems. The combination of better formulations, purification methods, and novel applications suggests mRNA therapeutics are entering a more mature phase with broader clinical potential.

Studies in this issue

Primary sources used for this newsletter.

  1. Using COVID-19 and other mRNA vaccines to improve cancer immunotherapy: how they work and future possibilities
    main storyJournal for immunotherapy of cancer2026-06-03PMID 42236116
  2. Safety and immune response of the mRNA mpox vaccine BNT166a in a first human trial with increasing doses
    key findingThe Lancet. Infectious diseases2026-06-03PMID 42235570
  3. Immune responses in the NextCOVE trial of the new mRNA-1283 COVID-19 vaccine
    key findingHuman vaccines & immunotherapeutics2026-06-01PMID 42220116
  4. Designing an mRNA antibody mix with longer treatment time against ricin poisoning
    key findingApplied microbiology and biotechnology2026-06-04PMID 42240837
  5. Continuous Purification of Lab-Made mRNA Using Advanced Membrane Technology
    key findingBiotechnology and bioengineering2026-06-03PMID 42236644
  6. Antioxidant lipid nanoparticles help keep mRNA stable for tissue repair and gene editing
    key findingNature communications2026-06-04PMID 42243120
  7. Lung surfactants in fat-based nanoparticles for delivering mRNA to the lungs
    key findingbioRxiv : the preprint server for biology2026-06-04PMID 42239299

Continue reading

All mRNA Technology issues